All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: tni.ohw@snoissimrep).
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Overview
This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalised anxiety and sleep disorders; obsessive-compulsive disorders and panic attacks; and alcohol and opioid dependence.
This manual is a reference source to assist physicians working in the primary health care through increasing their knowledge and improving their routine clinical practice in using medicines for mental disorders. It is though a reference source about pharmacological treatments only, and does not cover the overall management of mental disorders.
It is hoped that use of this manual will enhance the knowledge and competence of those health professionals who are at the forefront of health care delivery in resource poor health systems. This will facilitate much needed scaling-up services for person with mental, neurological and substance use disorders envisaged in mental health Gap Action Programme of the World Health Organization.
Contents
- Acknowledgements
- Foreword
- Preface
- Chapter 1. Essential medicines for mental disorders
- Chapter 2. Basic principles of prescribing
- Chapter 3. Medicines used in psychotic disorders
- 1 Definition of psychotic disorders
- 2 Preliminary assessment and initial management strategies
- 3 Short-term treatment with antipsychotics
- 4 Long-term treatment with antipsychotics
- 5 Administration of antipsychotics
- 6 Adverse reactions of antipsychotics
- 7 Overdosage of antipsychotics
- 8 Special patient populations
- 9 Potentially relevant interactions
- 10 Essential medicines for psychotic disorders
- Chapter 4. Medicines used in depressive disorders
- 1 Definition of depressive disorders
- 2 Preliminary assessment and initial management strategies
- 3 Short-term treatment with antidepressants
- 4 Long-term treatment with antidepressants
- 5 Administration of antidepressants
- 6 Adverse reactions of antidepressants
- 7 Overdosage of antidepressants
- 8 Special patient populations
- 9 Potentially relevant interactions
- 10 Essential medicines for depressive disorders
- Chapter 5. Medicines used in bipolar disorders
- 1 Definition of bipolar disorders
- 2 Preliminary assessment and initial management strategies
- 3 Short-term treatment with antimanic medicines
- 4 Long-term treatment with antimanic medicines
- 5 Administration of antimanic medicines
- 6 Adverse reactions of antimanic medicines
- 7 Overdosage of antimanic medicines
- 8 Special patient populations
- 9 Potentially relevant interactions
- 10 Essential medicines for bipolar disorders
- Chapter 6. Medicines used in generalized anxiety and sleep disorders
- 1 Definition of generalized anxiety and sleep disorders
- 2 Preliminary assessment and initial management strategies
- 3 Short-term treatment with benzodiazepines
- 4 Long-term treatment with benzodiazepines
- 5 Administration of benzodiazepines
- 6 Adverse reactions of benzodiazepines
- 7 Overdosage of benzodiazepines
- 8 Special patient populations
- 9 Potentially relevant interactions
- 10 Essential medicines for generalized anxiety and sleep disorders
- Chapter 7. Medicines used in obsessive-compulsive disorders and panic attacks
- 1 Definition of obsessive-compulsive disorders and panic attacks
- 2 Preliminary assessment and initial management strategies
- 3 Short-term treatment with antidepressants
- 4 Long-term treatment with antidepressants
- 5 Administration of antidepressants
- 6 Adverse reactions of antidepressants
- 7 Overdosage of antidepressants
- 8 Special patient populations
- 9 Potentially relevant interactions
- 10 Essential medicines for obsessive-compulsive and panic disorders
- Chapter 8. Medicines used in alcohol and opioid dependence
- 1 Definition of alcohol and opioid dependence
- 2 Preliminary assessment and initial management strategies
- 3 Short-term treatment (management of alcohol withdrawal, Wernicke-Korsokoff syndrome and commencement of relapse prevention medication for alcohol dependence)
- 4 Short-term treatment (management of opioid withdrawal and commencement of agonist maintenance treatment)
- 5 Long-term treatment
- 6 Administration
- 7 Adverse reactions
- 8 Overdosage
- 9 Special patient populations
- 10 Potentially relevant interactions
- 11 Essential medicines for opioid dependence
- Chapter 9. Essential references and source documents
- Spanish
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.
- NLM CatalogRelated NLM Catalog Entries
- Review Global Priorities for Addressing the Burden of Mental, Neurological, and Substance Use Disorders.[Mental, Neurological, and Subs...]Review Global Priorities for Addressing the Burden of Mental, Neurological, and Substance Use Disorders.Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, Ferrari AJ, Hyman S, Laxminarayan R, Levin C, et al. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). 2016 Mar 14
- Review Update of the Mental Health Gap Action Programme (mhGAP) Guidelines for Mental, Neurological and Substance Use Disorders, 2015[ 2015]Review Update of the Mental Health Gap Action Programme (mhGAP) Guidelines for Mental, Neurological and Substance Use Disorders, 2015. 2015 May
- Review [Alpha-interferon and mental disorders].[Encephale. 2001]Review [Alpha-interferon and mental disorders].Debien C, De Chouly De Lenclave MB, Foutrein P, Bailly D. Encephale. 2001 Jul-Aug; 27(4):308-17.
- Review Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010.[Mental, Neurological, and Subs...]Review Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010.Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). 2016 Mar 14
- Review Scale up services for mental disorders: a call for action.[Lancet. 2007]Review Scale up services for mental disorders: a call for action.Lancet Global Mental Health Group, Chisholm D, Flisher AJ, Lund C, Patel V, Saxena S, Thornicroft G, Tomlinson M. Lancet. 2007 Oct 6; 370(9594):1241-52.
- Pharmacological Treatment of Mental Disorders in Primary Health CarePharmacological Treatment of Mental Disorders in Primary Health Care
- LOC130063608 [Homo sapiens]LOC130063608 [Homo sapiens]Gene ID:130063608Gene
- LOC124908072 [Homo sapiens]LOC124908072 [Homo sapiens]Gene ID:124908072Gene
- LOC127890503 [Homo sapiens]LOC127890503 [Homo sapiens]Gene ID:127890503Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...